{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:16Z","timestamp":1793212036142,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NO. 81800497"],"award-info":[{"award-number":["NO. 81800497"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inflammatory Bowel Disease (IBD) affects reproductive-aged women. Active disease can lead to decreased fertility. Although the vast majority of international guidelines recommend for the continuation of anti-TNF-\u03b1 during pregnancy, recent studies have raised concerns about the safety of anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) therapy during pregnancy, both for patients and for physicians.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Studies that evaluate the safety of anti-TNF-\u03b1 therapy in pregnant women with IBD were identified using bibliographical searches. An updated meta-analysis was performed for pregnancy outcomes, such as live birth, abortion, still birth, preterm birth, low birth weight, congenital abnormalities, and neonatal infection. Odds ratio (OR) with 95% confidence interval (CI) are reported. Data on disease activity, timing of anti-TNF-\u03b1 therapy were collected for further analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 11 studies were screened from on-line databases and international meeting abstracts. An increased risk of abortion (OR, 1.33; 95% CI, 1.02\u20131.74; <jats:italic>P<\/jats:italic>\u2009=\u20090.04) and preterm birth (OR, 1.16; 95% CI, 1.05\u20131.28; <jats:italic>P<\/jats:italic>\u2009=\u20090.004), and a decreased risk of live birth (OR, 0.83; 95% CI, 0.74\u20130.94; <jats:italic>P<\/jats:italic>\u2009=\u20090.002]) were found in the anti-TNF-\u03b1 therapy group compared with the control group (no use of anti-TNF-\u03b1 therapy). The subgroup analyses based on the disease activity showed there is no significant association between the use of anti-TNF-\u03b1 therapy during pregnancy on adverse pregnancy outcomes of abortion, preterm birth, and live birth. The rates of still birth, low birth weight, and congenital abnormalities in the anti-TNF-\u03b1 therapy group were not significantly different from those in the control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-TNF-\u03b1 therapy does not increase the risks of still birth, low birth weight, and congenital abnormalities; however it may be assicated with increased risks of abortion and preterm birth, which are accompanied by a lower rate of live birth. Although these findings may be confounding by potential disease activity, they offer some opposite viewpoints with biologic agent use. Therefore, more studies are required to further confirm the safety of anti-TNF-\u03b1 therapy in pregnancy with IBD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-024-06443-w","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:02:14Z","timestamp":1712556134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-tumor necrosis factor-\u03b1 therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"3","key":"6443_CR1","first-page":"287","volume":"44","author":"P Munkholm","year":"1997","unstructured":"Munkholm P. Crohn\u2019s disease\u2013occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull. 1997;44(3):287\u2013302.","journal-title":"Dan Med Bull"},{"issue":"2","key":"6443_CR2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0016-5085(91)90202-V","volume":"100","author":"A Ekbom","year":"1991","unstructured":"Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991;100(2):350\u20138.","journal-title":"Gastroenterology"},{"issue":"7","key":"6443_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/j.1572-0241.2006.00603.x","volume":"101","author":"CN Bernstein","year":"2006","unstructured":"Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101(7):1559\u201368.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"6443_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","volume":"15","author":"MA Kim","year":"2021","unstructured":"Kim MA, Kim YH, Chun J, Lee HS, Park SJ, Cheon JH, et al. The influence of Disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and Meta-analysis. J Crohn\u2019s Colitis. 2021;15(5):719\u201332.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"6443_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/ajg.2010.464","volume":"106","author":"U Mahadevan","year":"2011","unstructured":"Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, et al. The London position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106(2):214\u201323. quiz 24.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"6443_CR6","first-page":"A65","volume":"1","author":"S Traussnigg","year":"2013","unstructured":"Traussnigg S, Eser A, Primas C, Papay P, Gratzer C, Mikulits A, et al. Adalimumab (ADA) and infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety, anti-TNFa cord blood and follow up blood levels in newborns. United Eur Gastroenterol J. 2013;1(1):A65\u20136.","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"6443_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","volume":"11","author":"Z Zelinkova","year":"2013","unstructured":"Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2013;11(3):318\u201321.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"2","key":"6443_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.placenta.2008.10.012","volume":"30","author":"S Haider","year":"2009","unstructured":"Haider S, Kn\u00f6fler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2009;30(2):111\u201323.","journal-title":"Placenta"},{"issue":"2","key":"6443_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1023\/A:1021740108284","volume":"20","author":"V Toder","year":"2003","unstructured":"Toder V, Fein A, Carp H, Torchinsky A. TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Genet. 2003;20(2):73\u201381.","journal-title":"J Assist Reprod Genet"},{"issue":"6","key":"6443_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1136\/gutjnl-2022-329304","volume":"72","author":"R Laube","year":"2023","unstructured":"Laube R, Selinger CP, Seow CH, Christensen B, Flanagan E, Kennedy D, et al. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut. 2023;72(6):1040\u201353.","journal-title":"Gut"},{"issue":"10","key":"6443_CR11","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","volume":"20","author":"N Narula","year":"2014","unstructured":"Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNF alpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and Meta-analysis. Inflamm Bowel Dis. 2014;20(10):1862\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"6443_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/ecco-jcc\/jjv234","volume":"10","author":"Z Shihab","year":"2016","unstructured":"Shihab Z, Yeomans ND, De Cruz P. Anti-tumour necrosis factor \u03b1 therapies and inflammatory bowel disease pregnancy outcomes: a Meta-analysis. J Crohn\u2019s Colitis. 2016;10(8):979\u201388.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"4","key":"6443_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bcp.12642","volume":"80","author":"C Weber-Schoendorfer","year":"2015","unstructured":"Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727\u201339.","journal-title":"Br J Clin Pharmacol"},{"issue":"SUPPL","key":"6443_CR14","first-page":"S359","volume":"116","author":"I Garrido","year":"2021","unstructured":"Garrido I, Lu\u00edsa Santos A, Lopes S, Macedo G. Risk factors for adverse pregnancy outcomes in inflammatory bowel disease. Am J Gastroenterol. 2021;116(SUPPL):S359.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"6443_CR15","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","volume":"113","author":"M Luu","year":"2018","unstructured":"Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous Anti-TNF\u03b1 use throughout pregnancy: possible complications for the Mother but not for the Fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018;113(11):1669\u201377.","journal-title":"Am J Gastroenterol"},{"key":"6443_CR16","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"9","key":"6443_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"7414","key":"6443_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Res ed). 2003;327(7414):557\u201360.","journal-title":"BMJ (Clinical Res ed)"},{"key":"6443_CR19","doi-asserted-by":"crossref","unstructured":"Rothstein HR, Sutton AJ, Borensein M. e. Publication Bias in Meta-Analysis\u2014Prevent, Assessment, and Adjustments. West Sussex, United Kingdom2005 2005. 193\u2013220 p.","DOI":"10.1002\/0470870168"},{"issue":"4","key":"6443_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/apt.12833","volume":"40","author":"M Seirafi","year":"2014","unstructured":"Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(4):363\u201373.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"6443_CR21","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, et al. Pregnancy outcomes reported during the 13-Year TREAT Registry: a descriptive report. Am J Gastroenterol. 2018;113(11):1678\u201388.","journal-title":"Am J Gastroenterol"},{"key":"6443_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","volume":"43","author":"O Diav-Citrin","year":"2014","unstructured":"Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reproductive Toxicol (Elmsford NY). 2014;43:78\u201384.","journal-title":"Reproductive Toxicol (Elmsford NY)"},{"issue":"3","key":"6443_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/apt.16448","volume":"54","author":"A Meyer","year":"2021","unstructured":"Meyer A, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and\/or anti-TNF: a French nationwide study 2010\u20132018. Aliment Pharmacol Ther. 2021;54(3):302\u201311.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"6443_CR24","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/ibd.21583","volume":"17","author":"F Schnitzler","year":"2011","unstructured":"Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17(9):1846\u201354.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"6443_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/ajg.2012.430","volume":"108","author":"MJ Casanova","year":"2013","unstructured":"Casanova MJ, Chaparro M, Dom\u00e8nech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, et al. Safety of thiopurines and anti-TNF-\u03b1 drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(3):433\u201340.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"6443_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5217\/ir.2016.14.2.139","volume":"14","author":"S Komoto","year":"2016","unstructured":"Komoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, et al. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and\/or thiopurine therapy: a multicenter study from Japan. Intestinal Res. 2016;14(2):139\u201345.","journal-title":"Intestinal Res"},{"issue":"1","key":"6443_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apt.15539","volume":"51","author":"A Moens","year":"2020","unstructured":"Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129\u201338.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"6443_CR28","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/S0016-5085(12)60561-7","volume":"142","author":"U Mahadevan","year":"2012","unstructured":"Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, et al. PIANO: a 1000 patient prospective Registry of pregnancy outcomes in women with IBD exposed to Immunomodulators and Biologic Therapy. Gastroenterology. 2012;142(5):S149\u2013S.","journal-title":"Gastroenterology"},{"key":"6443_CR29","unstructured":"Johnson D, Luo Y, Jones KL, Chambers C. Pregnancy outcomes in women exposed to adalimumab: an update on the autoimmune diseases in pregnancy project. Arthritis Rheum. 2011;63(10)."},{"issue":"5","key":"6443_CR30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ibd.20082","volume":"13","author":"SR Marri","year":"2007","unstructured":"Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(5):591\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"6443_CR31","volume-title":"Introduction to meta-analysis","author":"MHL Borenstein","year":"2011","unstructured":"Borenstein MHL, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester, UK: Wiley; 2011."},{"key":"6443_CR32","doi-asserted-by":"publisher","first-page":"102676","DOI":"10.1016\/j.jaut.2021.102676","volume":"122","author":"L Barenbrug","year":"2021","unstructured":"Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek J, Joosten I, et al. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-\u03b1 during pregnancy: a systemic review and meta-analysis. J Autoimmun. 2021;122:102676.","journal-title":"J Autoimmun"},{"issue":"3","key":"6443_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/pds.4930","volume":"29","author":"G Br\u00f6ms","year":"2020","unstructured":"Br\u00f6ms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM, et al. Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020;29(3):316\u201327.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"6443_CR34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","volume":"160","author":"U Mahadevan","year":"2021","unstructured":"Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, et al. Pregnancy and neonatal outcomes after fetal exposure to Biologics and Thiopurines among Women with Inflammatory Bowel Disease. Gastroenterology. 2021;160(4):1131\u20139.","journal-title":"Gastroenterology"},{"issue":"3","key":"6443_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14740338.2021.1873948","volume":"20","author":"R Laube","year":"2021","unstructured":"Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn\u2019s disease and ulcerative colitis. Exp Opin Drug Saf. 2021;20(3):275\u201392.","journal-title":"Exp Opin Drug Saf"},{"key":"6443_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","volume":"8","author":"A Esteve-Sol\u00e9","year":"2017","unstructured":"Esteve-Sol\u00e9 A, Dey\u00e0-Mart\u00ednez \u00c0, Teixid\u00f3 I, Ricart E, Gompertz M, Torradeflot M, et al. Immunological changes in blood of newborns exposed to Anti-TNF-\u03b1 during pregnancy. Front Immunol. 2017;8:1123.","journal-title":"Front Immunol"},{"issue":"1","key":"6443_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ibd\/izz110","volume":"26","author":"M Julsgaard","year":"2020","unstructured":"Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, et al. Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on Disease Behavior and Birth outcomes. Inflamm Bowel Dis. 2020;26(1):93\u2013102.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"6443_CR38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","volume":"150","author":"GC Nguyen","year":"2016","unstructured":"Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto Consensus Statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734\u2013e571.","journal-title":"Gastroenterology"},{"issue":"2","key":"6443_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","volume":"9","author":"CJ van der Woude","year":"2015","unstructured":"van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn\u2019s Colitis. 2015;9(2):107\u201324.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"6443_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","volume":"17","author":"J Torres","year":"2023","unstructured":"Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, et al. European Crohn\u2019s and Colitis guidelines on sexuality, fertility, pregnancy, and Lactation. J Crohn\u2019s Colitis. 2023;17(1):1\u201327.","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-024-06443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-024-06443-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-024-06443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:04:10Z","timestamp":1712556250000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-024-06443-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6443"],"URL":"https:\/\/doi.org\/10.1186\/s12884-024-06443-w","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that there is no competing of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}